HomeCompareGNR vs ABBV

GNR vs ABBV: Dividend Comparison 2026

GNR yields 2.30% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $79.2K in total portfolio value
10 years
GNR
GNR
● Live price
2.30%
Share price
$74.67
Annual div
$1.72
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.1K
Annual income
$266.79
Full GNR calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GNR vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNR
Annual income on $10K today (after 15% tax)
$195.46/yr
After 10yr DRIP, annual income (after tax)
$226.77/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,829.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNR + ABBV for your $10,000?

GNR: 50%ABBV: 50%
100% ABBV50/50100% GNR
Portfolio after 10yr
$62.7K
Annual income
$12,519.27/yr
Blended yield
19.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GNR
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNR buys
6
ABBV buys
0
PoliticianChamberTickerTypeAmountDate
Thomas R. Carper🏛 Senate$GNR▼ Sell$1,001 - $15,0002023-02-15
Thomas R. Carper🏛 Senate$GNR▼ Sell$1,001 - $15,0002023-02-15
Thomas R. Carper🏛 Senate$GNR▼ Sell$1,001 - $15,0002022-08-10
Thomas R. Carper🏛 Senate$GNR▼ Sell$1,001 - $15,0002022-08-10
Thomas R. Carper🏛 Senate$GNR▲ Buy$1,001 - $15,0002022-05-10
Thomas R. Carper🏛 Senate$GNR▲ Buy$1,001 - $15,0002022-05-10
Thomas R. Carper🏛 Senate$GNR▲ Buy$1,001 - $15,0002022-03-07
Thomas R. Carper🏛 Senate$GNR▲ Buy$1,001 - $15,0002022-03-07
Thomas R. Carper🏛 Senate$GNR▲ Buy$1,001 - $15,0002022-01-31
Thomas R. Carper🏛 Senate$GNR▲ Buy$1,001 - $15,0002022-01-31
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNRABBV
Forward yield2.30%3.06%
Annual dividend / share$1.72$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$23.1K$102.3K
Annual income after 10y$266.79$24,771.77
Total dividends collected$2.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GNR vs ABBV ($10,000, DRIP)

YearGNR PortfolioGNR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,930$229.96$11,550$430.00$620.00ABBV
2$11,930$234.90$13,472$627.96$1.5KABBV
3$13,005$239.62$15,906$926.08$2.9KABBV
4$14,159$244.12$19,071$1,382.55$4.9KABBV
5$15,399$248.40$23,302$2,095.81$7.9KABBV
6$16,729$252.47$29,150$3,237.93$12.4KABBV
7$18,156$256.34$37,536$5,121.41$19.4KABBV
8$19,687$260.01$50,079$8,338.38$30.4KABBV
9$21,329$263.49$69,753$14,065.80$48.4KABBV
10$23,089$266.79$102,337$24,771.77$79.2KABBV

GNR vs ABBV: Complete Analysis 2026

GNRStock

The State Street SPDR S&P Global Natural Resources ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Global Natural Resources Index (the "Index")Seeks to provide exposure to a number of the largest market cap securities in three natural resources sectors - agriculture, energy, and metals and miningMaximum weight of each sub-index is capped at one-third of the total weight of the Index

Full GNR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GNR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNR vs SCHDGNR vs JEPIGNR vs OGNR vs KOGNR vs MAINGNR vs JNJGNR vs MRKGNR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.